FDA Panel Supports Roche Rheumatoid Arthritis Drug

July 30, 2008

An FDA panel has come out and recommended that the FDA approve a new rheumatoid arthritis drug from Roche Holdings AG, Actemra..Boston (ChattahBox) – An FDA panel has come out and recommended that the FDA approve a new rheumatoid arthritis drug from Roche Holdings AG, Actemra.

The rheumatoid arthritis drug Actemra does not come without its fair share of issues, such as causing liver problems, infections, etc.

The FDA panel, made up of medical experts, has stated though that the benefits of the new drug far outweigh the risks.

Roche has been working to get it approved to treat rheumatoid arthritis, which causes chronic pain for patients, and joint issues.

Typically, the FDA follows the advice of their panels.


Comments

Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of ChattahBox.com - Comments are the opinions of the individuals leaving them, and not of ChattahBox.com or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.